台中榮民總醫院雙極雄性賀爾蒙治療案例經驗

林奕豪、李建儀、王賢祥、楊晨洸、陳卷書

台中榮民總醫院 泌尿醫學部

Bipolar androgen therapy in VGHTC

Yi-Hao Lin, Jian-Ri Li, Shian-Shiang Wang, Cheng-Kuang Yang, Chuan-Shu Chen 

Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan

Purpose: We assess the prognosis and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of third-line treatments, who underwent bipolar androgen therapy (BAT).

Materials and Methods: Five patients were enrolled in this study, all of whom received bipolar androgen therapy (BAT). The treatment that the patients have received and fluctuations in PSA levels were presented in graphic. Survival outcomes and quality of life were recorded.

Results: Four out of five patients demonstrated a survival duration exceeding 10 months post BAT. These four patients exhibited improvement in PSA levels within 3 months of initiating BAT. Improved quality of life and appetite were also mentioned. One patient dead within one month of BAT initiation.

Conclusions: Bipolar androgen therapy demonstrates a feasible treatment option after the failure of third-line treatments patients with mCRPC, potentially extending survival periods. Its features include economic feasibility and reported improvements in patients' quality of life. Analysis of the case resulting in death within one month of BAT initiation suggests that patients with poorer ECOG performance status may not be suitable candidates for this treatment. In Taiwan, further prospective studies are needed to evaluate efficacy and safety of BAT.